Drilldown: Medicines
Medicines > classes 
:
Analgesic or
[[:Category:Crystalloid_IV_fluids|Crystalloid IV fluid]] or
dissociative
:
Analgesic or
[[:Category:Crystalloid_IV_fluids|Crystalloid IV fluid]] or
dissociative Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Butorphanol (1) ·
Codeine (2) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextropropoxyphene (1) ·
Dextrorphan (1) ·
Dihydrocodeine (1) ·
Diphenidine (1) ·
Ephenidine (1) ·
Ethylmorphine (1) ·
Eticyclidine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Ibogaine (1) ·
Lactated Ringer's solution (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Methoxetamine (1) ·
Nalbuphine (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Sodium chloride (1) ·
Tapentadol (1) ·
Xenon (1)
brand:
None (22) ·
(multiple, generic dominant) (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
DXM (1) ·
DXO (1) ·
Lactated Ringer's Injection (Baxter, B. Braun, ICU Medical); Hartmann's solution (intl.) (1) ·
Normal saline, NaCl injection, many; nebulized: HyperSal, PulmoSal (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Spravato (1) ·
Stadol (1) ·
Talwin (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
'"`UNIQ--vote-00000037-QINU`"' Hypertonic 3% is the standard urgent treatment of severely symptomatic hyponatremia'"`UNIQ--ref-00000038-QINU`"'. (1) ·
'"`UNIQ--vote-00000086-QINU`"' Calcium content is a relative contraindication for co-administration with citrated blood products through the same line'"`UNIQ--ref-00000087-QINU`"'. (1)
uses:
None (34) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000039-QINU`"', '"`UNIQ--vote-0000003A-QINU`"', '"`UNIQ--vote-0000003B-QINU`"', '"`UNIQ--vote-0000003C-QINU`"', '"`UNIQ--vote-0000003D-QINU`"' (1) ·
'"`UNIQ--vote-00000088-QINU`"', '"`UNIQ--vote-00000089-QINU`"', '"`UNIQ--vote-0000008A-QINU`"', '"`UNIQ--vote-0000008B-QINU`"' (1)
starting dose:
None (34) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
Volume and concentration titrated to clinical status; symptomatic hyponatremia: 3% NaCl 100-150 mL bolus, reassess (1) ·
Volume titrated to clinical status; typical adult bolus 500-1000 mL, then reassess (1)
preparations:
None (34) ·
0.225%, 0.45%, 0.9%, 3%, 5% IV solutions; 0.9% nasal spray; 3% and 7% nebulizer solutions; oral tablets (1 g) (1) ·
250, 500, 1000 mL IV bags. Composition per liter: Na+ 130 mEq, K+ 4 mEq, Ca2+ 3 mEq, Cl- 109 mEq, lactate 28 mEq (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
legal:
None (34) ·
Rx, Schedule III (US). REMS program required. (1) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] for parenteral formulations; OTC for oral, nasal, and many nebulizer products (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1)
Showing below up to 38 results in range #1 to #38.